alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.3375 *Mycoplasma* spp. serological reagents. ( a ) *Identification. Mycoplasma* spp. serological reagents are devices that consist of antigens and antisera used in serological tests to identify antibodies to *Mycoplasma* spp. in serum. Additionally, some of these reagents consist of *Mycoplasma* spp. antisera conjugated with a fluorescent dye (immunofluorescent reagents) used to identify *Mycoplasma* spp. directly from clinical specimens. The identification aids in the diagnosis of disease caused by bacteria belonging to the genus *Mycoplasma* and provides epidemiological information on diseases caused by these microorganisms. *Mycoplasma* spp. are associated with inflammatory conditions of the urinary and respiratory tracts, the genitals, and the mouth. The effects in humans of infection with *Mycoplasma pneumoniae* range from inapparent infection to mild or severe upper respiratory disease, ear infection, and bronchial pneumonia.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 866.9.
[47 FR 50823, Nov. 9, 1982, as amended at 65 FR 2311, Jan. 14, 2000]
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 6-K

       REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
                    UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of                   March                                 , 2003.
                ----------------------------------------------------------------

                                Group Simec, Inc.
--------------------------------------------------------------------------------
                 (Translation of Registrant's Name Into English)

                                     Mexico
--------------------------------------------------------------------------------
                 (Jurisdiction of incorporation or organization)

Av. Lazaro Cardenas 601, Colonia la Nogalera, Guadalajara, Jalisco, Mexico 44440
--------------------------------------------------------------------------------
                     (Address of principal executive office)

(Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F.)

         Form 20-F [X]            Form 40-F [ ]

(Indicate by check mark whether the registrant by furnishing the information
contained in this form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.)

         Yes [ ]            No [X]

(If "Yes" is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g3-2(b):
82-_______________________.)


<PAGE>

                                    SIGNATURE

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
Company has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.

                                                     GRUPO SIMEC, S.A. de C.V.
                                                     -------------------------
                                                           (Registrant)

Date: March    , 2003.                            By: /s/ Luis Garcia Limon
                                                      --------------------------
                                                  Name:  Luis Garcia Limon
                                                  Title: Chief Executive Officer
§ 71.2 Notice of filing of petition. ( a ) Except where the petition involves a new drug, the Commissioner, within 15 days after receipt, will notify the petitioner of acceptance or nonacceptance of a petition, and if not accepted the reasons therefor. If accepted, the date of the notification letter sent to petitioner becomes the date of filing for the purposes of section 721(d)(1) of the act. If the petitioner desires, he may supplement a deficient petition after being notified regarding deficiencies. If the supplementary material or explanation of the petition is deemed acceptable, petitioner shall be notified. The date of such notification becomes the date of filing. If the petitioner does not wish to supplement or explain the petition and requests in writing that it be filed as submitted, the petition shall be filed and the petitioner so notified. The date of such notification becomes the date of filing. Where the petition involves a new drug, notification to the petitioner will be made in accordance with § 70.10(b)(3) of this chapter.
( b ) The Commissioner will cause to be published in the Federal Register within 30 days from the date of filing of such petition a notice of the filing, the name of the petitioner, and a brief description of the proposal in general terms. A copy of the notice will be mailed to the petitioner when the original document is signed.
[42 FR 15639, Mar. 22, 1977, as amended at 64 FR 400, Jan. 5, 1999]
**Exhibit 23.1**

 

**Consent of Independent Auditors**

 

We consent to the incorporation by reference in the post effective amendment no. 1 registration statement on Form S-8 of 1st Independence Financial Group, Inc. (Company) (333-113163) and in the registration statement of the Company on Form S-8 (333-118198) of our report dated March4, 2005, appearing in the annual report on Form 10-KSB of the Company for the three months ended December 31, 2004. 

 

/s/ **BKD, LLP**

 

Louisville, Kentucky 

March 28, 2005
# C_2015007EN.01006001.xml

| 12.1.2015 | EN | Official Journal of the European Union | C 7/60 |
| --- | --- | --- | --- |

12.1.2015

EN

Official Journal of the European Union

C 7/60

---

Action brought on 27th October 2014 — ZZ v Parliament

(Case F-125/14)

(2015/C 007/77)

Language of the case: English

Parties

Parties

Applicant: ZZ (represented by: L. Levi and C. Bernard-Glanz, lawyers)

Applicant:

Defendant: Parliament

Defendant:

Subject-matter and description of the proceedings

Subject-matter and description of the proceedings

The annulment of the decision of the Parliament to dismiss the applicant and the payment of damages.

Form of order sought

Form of order sought

| — | Annul the contested decision and, so far as necessary, the decision rejecting the complaint; |
| --- | --- |

—

Annul the contested decision and, so far as necessary, the decision rejecting the complaint;

| — | order the defendant to pay the applicant the salary and allowances she should have earned until the end of the 2009-2014 legislature; |
| --- | --- |

—

order the defendant to pay the applicant the salary and allowances she should have earned until the end of the 2009-2014 legislature;

| — | order the defendant to award the applicant an amount of 50  000 €, ex aequo et bono, and subject to increase or decrease in the course of the proceedings, as compensation for the damage resulting from the loss of the chance to securing a job at the European Parliament after the 2009-2014 legislature; |
| --- | --- |

—

order the defendant to award the applicant an amount of 50  000 €, ex aequo et bono, and subject to increase or decrease in the course of the proceedings, as compensation for the damage resulting from the loss of the chance to securing a job at the European Parliament after the 2009-2014 legislature;

| — | order the defendant to award the applicant an amount of 15  000 €, ex aequo et bono, and subject to increase or decrease in the course of the proceedings, as compensation for the non-material damage suffered; |
| --- | --- |

—

order the defendant to award the applicant an amount of 15  000 €, ex aequo et bono, and subject to increase or decrease in the course of the proceedings, as compensation for the non-material damage suffered;

| — | order the defendant to pay the costs. |
| --- | --- |

—

order the defendant to pay the costs.

---
§ 814.37 PMA amendments and resubmitted PMAs. ( a ) An applicant may amend a pending PMA or PMA supplement to revise existing information or provide additional information.
( b ) ( 1 ) FDA may request the applicant to amend a PMA or PMA supplement with any information regarding the device that is necessary for FDA or the appropriate advisory committee to complete the review of the PMA or PMA supplement.
( 2 ) FDA may request the applicant to amend a PMA or PMA supplement with information concerning pediatric uses as required under §§ 814.20(b)(13) and 814.39(c)(2).
( c ) A PMA amendment submitted to FDA shall include the PMA or PMA supplement number assigned to the original submission and, if submitted on the applicant's own initiative, the reason for submitting the amendment. FDA may extend the time required for its review of the PMA, or PMA supplement, as follows: ( 1 ) If the applicant on its own initiative or at FDA's request submits a major PMA amendment (e.g., an amendment that contains significant new data from a previously unreported study, significant updated data from a previously reported study, detailed new analyses of previously submitted data, or significant required information previously omitted), the review period may be extended up to 180 days.
( 2 ) If an applicant declines to submit a major amendment requested by FDA, the review period may be extended for the number of days that elapse between the date of such request and the date that FDA receives the written response declining to submit the requested amendment.
( d ) An applicant may on its own initiative withdraw a PMA or PMA supplement. If FDA requests an applicant to submit a PMA amendment and a written response to FDA's request is not received within 180 days of the date of the request, FDA will consider the pending PMA or PMA supplement to be withdrawn voluntarily by the applicant.
( e ) An applicant may resubmit a PMA or PMA supplement after withdrawing it or after it is considered withdrawn under paragraph (d) of this section, or after FDA has refused to accept it for filing, or has denied approval of the PMA or PMA supplement. A resubmitted PMA or PMA supplement shall comply with the requirements of § 814.20 or § 814.39, respectively, and shall include the PMA number assigned to the original submission and the applicant's reasons for resubmission of the PMA or PMA supplement.
[51 FR 26364, July 22, 1986, as amended at 79 FR 1740, Jan. 10, 2014]
Editorial Note on Part 878
Editorial Note: Nomenclature changes to part 878 appear at 73 FR 35341, June 23, 2008.

§ 878.4380 Drape adhesive. ( a ) *Identification.* A drape adhesive is a device intended to be placed on the skin to attach a surgical drape.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 878.9.
[53 FR 23872, June 24, 1988, as amended at 59 FR 63010, Dec. 7, 1994; 66 FR 38802, July 25, 2001]
I 

118TH CONGRESS 

2D SESSION H. R. 7826 

To amend the Omnibus Crime Control and Safe Streets Act of 1968 with 

respect to certain grants authorized for Edward Byrne Memorial Justice 

Assistance Grant Program. 

IN THE HOUSE OF REPRESENTATIVES 

MARCH 26, 2024 

Mr. SCHIFF (for himself, Mr. HUFFMAN, Mr. ESPAILLAT, Mr. RUIZ, Ms. 

MOORE of Wisconsin, Ms. SALINAS, Ms. TITUS, and Ms. BROWNLEY) introduced the following bill; which was referred to the Committee on the 

Judiciary 

A BILL 

To amend the Omnibus Crime Control and Safe Streets 

Act of 1968 with respect to certain grants authorized 

for Edward Byrne Memorial Justice Assistance Grant 

Program. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Tribal Community 

5 Protection Act of 2024’’. 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
2 

•HR 7826 IH

1 SEC. 2. GRANTS AUTHORIZED FOR EDWARD BYRNE MEMO2 RIAL JUSTICE ASSISTANCE GRANT PROGRAM. 

3 Section 501 of the Omnibus Crime Control and Safe 

4 Streets Act of 1968 (34 U.S.C. 10152) is amended to read 

5 as follows: 

6 (1) in subsection (a)(1), by adding at the end 

7 the following: 

8 ‘‘(J) Programs to provide written notifica9 tion on any restraining order or temporary re10 straining order for the purpose of enforcement 

11 on tribal lands and enforcement of any such 

12 order issued by an Indian tribe.’’; and 

13 (2) by adding at the end the following: 

14 ‘‘(i) DEFINITIONS.—In this section: 

15 ‘‘(1) TRIBAL LANDS.—The term ‘tribal lands’ 

16 means lands the title to which is held by the United 

17 States in trust for an Indian tribe or lands the title 

18 to which is held by an Indian tribe subject to a re19 striction by the United States against alienation. 

20 ‘‘(2) INDIAN TRIBE.—The term ‘Indian tribe’ 

21 shall have the meaning given such term in section 

22 102 of the Federally Recognized Indian Tribe List 

23 Act of 1994. 

24 ‘‘(3) WRITTEN NOTIFICATION.—The term ‘writ25 ten notification’ means a notification that is sent by 

26 registered or certified mail, with return receipt reVerDate Sep 11 2014 04:09 Apr 12, 2024 Jkt 049200 PO 00000 Frm 00002 Fmt 6652 Sfmt 6201 E:\BILLS\H7826.IH H7826

kjohnson on DSK7ZCZBW3PROD with $$_JOB
3 

•HR 7826 IH

1 quested, to Indian tribes and for which a copy of 

2 such notification is sent to the appropriate Regional 

3 Director of the Bureau of Indian Affairs.’’. 

Æ 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
<TABLE> <S> <C>

<ARTICLE> 5
<CIK> 0000814576
<NAME> PAINEWEBBER R&D PARTNERS II, L.P.
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-END>                               MAR-31-1997
<CASH>                                           5,246
<SECURITIES>                                 1,965,358
<RECEIVABLES>                                  770,805
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                             1,791,532
<PP&E>                                               0
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                               2,741,409
<CURRENT-LIABILITIES>                           68,205
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                   2,673,204
<TOTAL-LIABILITY-AND-EQUITY>                 2,741,409
<SALES>                                              0
<TOTAL-REVENUES>                             4,696,925
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                72,869
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                              4,624,056
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 4,624,056
<EPS-PRIMARY>                                        0
<EPS-DILUTED>                                        0
        

</TABLE>
§ 876.5981 Oral removable palatal space occupying device for weight management and/or weight loss. ( a ) *Identification.* An oral removable palatal space occupying device for weight management and/or weight loss is a prescription device that is worn during meals to limit bite size, thereby reducing the amount of food that is consumed. The device may contain recording sensors for monitoring patient use. This classification does not include devices that are intended to treat any dental diseases or conditions
( b ) *Classification.* Class II (special controls). The special controls for this device are: ( 1 ) The patient-contacting components of the device must be demonstrated to be biocompatible for its intended use.
( 2 ) Non-clinical performance testing must demonstrate that the device performs as intended under anticipated conditions for use, as follows: ( i ) Mechanical testing must demonstrate that the device performs as intended for the labeled use life and does not create forces that result in movement of teeth and damage to teeth.
( ii ) Electrical safety and electromagnetic compatibility testing must demonstrate that the device performs as intended.
( iii ) Software verification and validation must demonstrate that the device performs as intended.
( iv ) Battery testing must demonstrate that the device battery performs as intended.
( 3 ) Clinical performance testing must demonstrate the device performs as intended and must include an evaluation for choking.
( 4 ) Device labeling must address the following: ( i ) Patient labeling must state: ( A ) The clinical benefit of weight management and/or weight loss as assessed by using percent total body weight loss;
( B ) Treatment must be offered in combination with a behavioral modification program;
( C ) Instructions on how to use the device as intended; and
( D ) The use life of the device.
( ii ) Physician labeling must state: ( A ) The clinical benefit of weight management and/or weight loss as assessed by using percent total body weight loss;
( B ) Treatment must be offered in combination with a behavioral modification program;
( C ) Instructions on how to use the device as intended; and
( D ) The use life of the device.
( 5 ) Training must be provided to health professionals that includes procedures for determining a patient's oral health status, instructions for making the palatal mold, and assessment of issues with the device that may require service by the manufacturer.
[82 FR 35069, July 28, 2017]
Editorial Note on Part 872
Editorial Note: Nomenclature changes to part 872 appear at 73 FR 35341, June 23, 2008.

§ 872.3890 Endodontic stabilizing splint. ( a ) *Identification.* An endodontic stabilizing splint is a device made of a material, such as titanium, intended to be inserted through the root canal into the upper or lower jaw bone to stabilize a tooth.
( b ) *Classification.* Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 872.9.
[52 FR 30097, Aug. 12, 1987, as amended at 84 FR 71812, Dec. 30, 2019]
§ 74.2707a Ext. D&C Yellow No. 7. ( a ) *Identity and specifications.* The color additive Ext. D&C Yellow No. 7 shall conform in identity and specifications to the requirements of § 74.1707a (a)(1) and (b).
( b ) *Uses and restrictions.* Ext. D&C Yellow No. 7 may be safely used for coloring externally applied cosmetics in amounts consistent with good manufacturing practice.
( c ) *Labeling.* The label of the color additive shall conform to the requirements of § 70.25 of this chapter.
( d ) *Certification.* All batches of Ext. D&C Yellow No. 7 shall be certified in accordance with regulations in part 80 of this chapter.
Grant of Extension of Time PAGE 1 IN THE SUPREME COURT OF THE STATE OF MONTANA

No. DA 2 0
- 0405 IN THE MATTER OF: A.J. and J.J, Youths in Need of Care.

**GRANT OF EXTENS ION OF TIME**  Upon consideration of the Appellant ’s Motion fo r Extension of T ime, and good cause appearing therefore, the Appellant is granted an extension of time until December 7 , 2020 to prepare, serve, and file the Opening Brief. No further extensions will be granted.

Electronically signed by: Mike McGrath Chief Justice, Montana Supreme Court

November 11 2020

11/12/2020
[Federal Register Volume 75, Number 42 (Thursday, March 4, 2010)]
[Notices]
[Page 9909]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-4483]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of General Medical Sciences; Notice of Closed 
Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of General Medical 
Sciences Special Emphasis Panel; MBRS SCORE Neuroscience & 
Physiology.
    Date: April 2, 2010.
    Time: 8:30 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Hyatt Regency, Bethesda, MD 20814.
    Contact Person: Brian R Pike, PhD, Scientific Review Officer, 
Office of Scientific Review, National Institute of General Medical 
Sciences, National Institutes of Health, 45 Center Drive, Room 
3AN18, Bethesda, MD 20892, 301-594-3907, <a href="/cdn-cgi/l/email-protection#52223b393020123f333b3e7c3c3b3a7c353d24"><span class="__cf_email__" data-cfemail="42322b292030022f232b2e6c2c2b2a6c252d34">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.375, 
Minority Biomedical Research Support; 93.821, Cell Biology and 
Biophysics Research; 93.859, Pharmacology, Physiology, and 
Biological Chemistry Research; 93.862, Genetics and Developmental 
Biology Research; 93.88, Minority Access to Research Careers; 93.96, 
Special Minority Initiatives, National Institutes of Health, HHS)

    Dated: February 25, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2010-4483 Filed 3-3-10; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>